Is ARS Pharmaceuticals, Inc. (SPRY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 35.1% / 30% | 1.0% / 30% | 12.75% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 35.1% / 33% | 1.0% / 33% | 12.75% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 89.4% / 33% | 2.6% / 33% | 12.75% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 35.1% / 33% | 1.0% / 33% | 12.75% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 89.4% / 33% | 2.6% / 50% | 12.75% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 60.1% | |
| Operating Margin | -147.6% | |
| Net Margin | -203.3% | |
| Return on Equity (ROE) | -92.3% | |
| Return on Assets (ROA) | -33.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$171M |
| Free Cash Flow | -$171M |
| Total Debt | $96M |
| Debt-to-Equity | 147.5 |
| Current Ratio | 7.3 |
| Total Assets | $328M |
Price & Trading
| Last Close | $8.56 |
| 50-Day MA | $9.31 |
| 200-Day MA | $11.60 |
| Avg Volume | 1.4M |
| Beta | 0.8 |
|
52-Week Range
$6.66
| |
About ARS Pharmaceuticals, Inc. (SPRY)
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ARS Pharmaceuticals, Inc. (SPRY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ARS Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ARS Pharmaceuticals, Inc.'s debt ratio?
ARS Pharmaceuticals, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are ARS Pharmaceuticals, Inc.'s key financial metrics?
ARS Pharmaceuticals, Inc. has a market capitalization of $801M, and revenue of $84M. The company maintains a gross margin of 60.1% and a net margin of -203.3%. Return on equity stands at -92.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.